Therapeutic Vaccination Strategies Against EBOV by RVSV-EBOV-GP: the Role of Innate Immunity

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2021 Nov 8

PMID 34749265

Citations 1

Authors

Amanda N Pinski

Ilhem Messaoudi

Affiliations

Soon will be listed here.

Abstract

Zaire Ebola virus (EBOV) is a member of the Filoviridae family. Infection with EBOV causes Ebola virus disease (EVD) characterized by excessive inflammation, lymphocyte death, coagulopathy, and multi-organ failure. In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo® by Merck). This live-recombinant vaccine confers both prophylactic and therapeutic protection to nonhuman primates and humans. While mechanisms conferring prophylactic protection are well-investigated, those underlying protection conferred shortly before and after exposure to EBOV remain poorly understood. In this review, we review data from in vitro and in vivo studies analyzing early immune responses to rVSV-EBOV-GP and discuss the role of innate immune activation in therapeutic protection.

Citing Articles

Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses.

Ouyang M, Ao Z, Olukitibi T, Lawrynuik P, Shieh C, Kung S Vaccines (Basel). 2023; 11(9).

PMID: 37766083 PMC: 10534613. DOI: 10.3390/vaccines11091404.

References

Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Palu G . Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses. 2019; 11(3). PMC: 6466262. DOI: 10.3390/v11030274. View

Prins K, Cardenas W, Basler C . Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol. 2009; 83(7):3069-77. PMC: 2655579. DOI: 10.1128/JVI.01875-08. View

Roberts A, Buonocore L, Price R, Forman J, Rose J . Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999; 73(5):3723-32. PMC: 104148. DOI: 10.1128/JVI.73.5.3723-3732.1999. View

Qiu X, Fernando L, Alimonti J, Melito P, Feldmann F, Dick D . Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009; 4(5):e5547. PMC: 2678264. DOI: 10.1371/journal.pone.0005547. View

Fuller C, Ruthel G, Warfield K, Swenson D, Bosio C, Aman M . NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol. 2007; 9(4):962-76. DOI: 10.1111/j.1462-5822.2006.00844.x. View

Tipton T, Hall Y, Bore J, White A, Sibley L, Sarfas C . Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. Nat Commun. 2021; 12(1):1153. PMC: 7895930. DOI: 10.1038/s41467-021-21411-0. View

Fries L, Cho I, Krahling V, Fehling S, Strecker T, Becker S . Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. J Infect Dis. 2019; 222(4):572-582. DOI: 10.1093/infdis/jiz518. View

Geisbert T, Daddario-DiCaprio K, Geisbert J, Reed D, Feldmann F, Grolla A . Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26(52):6894-900. PMC: 3398796. DOI: 10.1016/j.vaccine.2008.09.082. View

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti J . Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53. PMC: 4214273. DOI: 10.1038/nature13777. View

10.

Mire C, Geisbert J, Agans K, Satterfield B, Versteeg K, Fritz E . Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One. 2014; 9(4):e94355. PMC: 3997383. DOI: 10.1371/journal.pone.0094355. View

11.

Ayithan N, Bradfute S, Anthony S, Stuthman K, Dye J, Bavari S . Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways. J Interferon Cytokine Res. 2013; 34(2):79-89. PMC: 3924795. DOI: 10.1089/jir.2013.0035. View

12.

Cross R, Bornholdt Z, Prasad A, Geisbert J, Borisevich V, Agans K . Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. Nat Commun. 2020; 11(1):3736. PMC: 7385100. DOI: 10.1038/s41467-020-17446-4. View

13.

Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef S . Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Front Immunol. 2018; 9:1803. PMC: 6095993. DOI: 10.3389/fimmu.2018.01803. View

14.

Suder E, Furuyama W, Feldmann H, Marzi A, de Wit E . The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Hum Vaccin Immunother. 2018; 14(9):2107-2113. PMC: 6183239. DOI: 10.1080/21645515.2018.1473698. View

15.

Biron C, Nguyen K, Pien G, Cousens L, Salazar-Mather T . Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999; 17:189-220. DOI: 10.1146/annurev.immunol.17.1.189. View

16.

Cobleigh M, Bradfield C, Liu Y, Mehta A, Robek M . The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. J Virol. 2012; 86(8):4253-61. PMC: 3318607. DOI: 10.1128/JVI.05991-11. View

17.

Brown K, Safronetz D, Marzi A, Ebihara H, Feldmann H . Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol. 2011; 85(23):12781-91. PMC: 3209372. DOI: 10.1128/JVI.00794-11. View

18.

Kennedy S, Bolay F, Kieh M, Grandits G, Badio M, Ballou R . Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017; 377(15):1438-1447. PMC: 5705229. DOI: 10.1056/NEJMoa1614067. View

19.

Lai L, Davey R, Beck A, Xu Y, Suffredini A, Palmore T . Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA. 2015; 313(12):1249-55. PMC: 4874522. DOI: 10.1001/jama.2015.1995. View

20.

Wahl-Jensen V, Afanasieva T, Seebach J, Stroher U, Feldmann H, Schnittler H . Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol. 2005; 79(16):10442-50. PMC: 1182673. DOI: 10.1128/JVI.79.16.10442-10450.2005. View